Chronic kidney disease in people with type 2 diabetes is heavily prevalent, and the main causes are diabetes and hypertension. In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss the health burden of chronic kidney disease (CKD) in people with type 2 diabetes, SGLT-2 inhibitors and their role in improving renal outcomes, and the clinical evidence that supports their use in people with CKD with or without diabetes.
The abstract entitled: ‘Go with the Flozin: Clinical Implications of SGLT-2 Inhibitors for Chronic Kidney Disease’
was presented at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, 12-15 Aug, 2022.
Questions:
- Could you give us a brief overview of the health burden of chronic kidney disease (CKD) in people with type 2 diabetes (T2D)?
- What is the mechanism of action of SGLT-2 inhibitors in improving renal outcomes in T2D?
- What clinical evidence supports the use of SGLT-2 inhibitors in people with CKD with or without diabetes?
- How widespread is the use of SGLT-2 inhibitors in clinical practice?
- How can we optimize the use of SGLT-2 inhibitors?
Disclosures: Speaker’s bureau participant with Novo Nordisk on semaglutide.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ADCES 2022
Click here for more related content.
